ImmunityBio (IBRX) Rallies on 11th Day, Hits 52-Week High on Strong Clinical Trial Results

We recently published 10 Firms Making Effortless 10-40% Gains. ImmunityBio Inc. (NASDAQ:IBRX) was one of the top performers on Friday.

ImmunityBio's rally showed no signs of stopping, after extending gains for an 11th straight session on Friday to hit a new 52-week high, on the back of  a flurry of catalysts, including a 700 percent sales jump, its expansion to a new international market, as well as the promising results from the clinical trial of its treatment candidate for a rare blood cancer.

At intra-day trading, the stock soared to its highest price of $5.58 before trimming gains to end the session just up by 39.75 percent at $5.52 apiece.

In a statement, ImmunityBio Inc. (NASDAQ:IBRX) said that its CD19 CAR-NK treatment, in combination with rituximab, showed that the disease in four patients enrolled in the program was fully controlled, with two demonstrating complete remission at 7 and 15 months despite not receiving additional treatments after the initial eight doses.

After only two cycles, ImmunityBio Inc. (NASDAQ:IBRX) said the tumors disappeared completely, adding that the durability of complete response after ending the treatment underscores the potential for long-term immune-mediated disease control without continuous therapy.

In other developments, ImmunityBio Inc. (NASDAQ:IBRX) earlier this week announced a 700 percent jump in preliminary revenues from Anktiva at $113 million for the full-year 2025, amid strong demand.

It is also set expand operations in Saudi Arabia after securing the approval of its Food and Drug Administration to sell and market Anktiva.

While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.